Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

INFI / Infinity Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders -

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has 78 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23,798,585 shares. Largest shareholders include Bvf Inc/il, Vanguard Group Inc, Orbimed Advisors Llc, Renaissance Technologies LLC, Platinum Investment Management Ltd, BlackRock Inc., Deutsche Bank Ag\, Wellington Management Group Llp, Millennium Management Llc, and Baker Brothers Advisors LP. (105-4)

BiolineRx Has Huge Upside In 2018

2018-01-29 seekingalpha
In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents. (418-13)

Verastem: Updates To Thesis

2018-01-28 seekingalpha
Dilution occurred as predicted, although the amount was less than I would have thought in this case. (117-4)

Infinity Provides Update on Lead Candidate, Issues 2018 View

2018-01-26 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) provided an update on  lead pipeline candidate-IPI-549 and also issued financial guidance for 2018. (161-1)

Verastem: Looks Undervalued Despite Cash Concerns

2017-12-28 seekingalpha
Verastem reported positive top-line data for its lymphoma drug, Duvelisib; the company will submit an NDA in Q1 2018. (110-7)

Verastem: Too Cheap

2017-12-04 seekingalpha
A de-risked biotech company. Considerable newsflow during the next 12 months. The presentation of P3 data at American Soc. of Hematology, Dec 10, 2017) will likely lead to greater awareness. (177-11)

Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock

2017-11-14 zacks
Investors in Infinity Pharmaceuticals, Inc. (INFI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17th 2017 $3.00 Call had some of the highest implied volatility of all equity options today. (97-3)

Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity"), following which we have published a free report that can be viewed by signing up at The Company announced on November 10, 2017, Phase-1 clinical and translational data for IPI-549, its oral immuno-oncology development candidate. (84-1)

Infinity Pharmaceuticals: When Safety Is A Win

2017-11-10 seekingalpha
Readers should pay attention to the safety and tolerability of IPI-549, not response rates in the monotherapy portion of the study. (141-1)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

ROTY Edition 1 Volume 48: Cutting A Position Loose And Promising Updates On Current Holdings

2017-11-08 seekingalpha
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)

Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

2017-11-08 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 14 cents per share in third-quarter 2017, narrower than the Zacks Consensus Estimate of a loss of  21 cents. The company had reported a loss of 39 cents in the year-ago quarter. (215-1)

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company’s Financial Results for the Third Quarter of 2017. My name is Glenda and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Infinity’s request. (141-0)

ROTY Volume 1 Edition 47: Understanding Mr. Market's Temper Tantrums And Updates

2017-11-07 seekingalpha
I touch on the importance of distinguishing between true high volume institutional selling and momentary temper tantrums thrown by Mr. Market. (98-0)

INFI : Infinity Pharmaceuticals Stock Analysis and Research Report

Infinity Pharmaceuticals is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity Pharmaceuticals is focusing its efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.

Preclinical research has demonstrated that PI3K-gamma is highly expressed in tumor-associated macrophages and that blockade of PI3K-gamma signaling by treatment with IPI-549 results in a reprogramming of macrophages in the tumor microenvironment from the M2, or pro-tumor, phenotype to the M1, or anti-tumor, phenotype. This shift increased the number and activity of anti-tumor T cells that can attack the tumor and also increased the production of pro-inflammatory cytokines, which can further stimulate an anti-tumor immune response. Preclinical data from multiple solid tumor models demonstrated that IPI-549 was active as a monothe...

Click for full article
CUSIP: 45665G303